Weekly NIH Funding Opportunities and Notices for March 26, 2021

Policy Notices

- Updated Reporting Requirements for RADx-rad Grant Recipients
  (NOT-OD-21-084)
  National Institutes of Health

- Continued Extension of Certain Flexibilities for Prospective Basic Experimental Studies With Human Participants
  (NOT-OD-21-088)
  National Institutes of Health

General Notices

- Notice of Information: NIAAA Clinical Medications Development Testing Program
  (NOT-AA-21-008)
  National Institute on Alcohol Abuse and Alcoholism

- Notice of Pre-Application Information Webinar for PAR-21-092, "NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use Disorders (UG3/UH3 Clinical Trial Optional)"
  (NOT-DA-21-025)
  National Institute on Drug Abuse

- Updated NHLBI Guidance Concerning Mentored Career Development (K08 and K23) Awards: Percent Effort
  (NOT-HL-21-003)
  National Heart, Lung, and Blood Institute

- Updated Notice of Limited Availability of Research Non-Human Primates
  (NOT-OD-21-080)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- Expansion of Eligibility: Technical and Business Assistance (TABA) Needs Assessment Program for National Institutes of Health (NIH) Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Awardees
  (NOT-OD-21-082)
  National Institutes of Health

- Request for Information: Challenges and Opportunities in Understanding Cellular Senescence and Senolytics
  (NOT-RM-21-016)
  Office of Strategic Coordination (Common Fund)

Notice of Changes to Funding Opportunities
• **Notice of Clarification of Research Priorities for RFA-AA-21-002 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed)"
  (NOT-AA-21-009)
  National Institute on Alcohol Abuse and Alcoholism

• **Notice of Clarification of Research Priorities for RFA-AA-21-003 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed)"
  (NOT-AA-21-010)
  National Institute on Alcohol Abuse and Alcoholism

• **Notice of Clarification of Research Priorities for RFA-AA-21-004 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)"
  (NOT-AA-21-011)
  National Institute on Alcohol Abuse and Alcoholism

• **Notice of Early Expiration of PAR-19-346 "Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)"
  (NOT-AI-21-033)
  National Institute of Allergy and Infectious Diseases

• **Notice of Early Expiration of PAR-19-347 "Investigations on Primary Immunodeficiency Diseases/Inborn Errors of Immunity (R03 Clinical Trial Not Allowed)"
  (NOT-AI-21-034)
  National Institute of Allergy and Infectious Diseases

• **Notice of Early Expiration of PA-19-068, Secondary Analysis of Existing Datasets for Advancing Infectious Disease Research (R21 Clinical Trial Not Allowed)"
  (NOT-AI-21-040)
  National Institute of Allergy and Infectious Diseases

• **Notice of Change to Eligibility Information in RFA-AI-20-080, "Human Immunology Project Consortium (HIPC) Coordinating Center (U01 Clinical Trial Not Allowed)"
  (NOT-AI-21-043)
  National Institute of Allergy and Infectious Diseases

• **Notice of Extension of Application Due Date for RFA-DK-20-034, "Program to Advance the Career Development of Scientists from Diverse Backgrounds Conducting Nutrition, Obesity, Diabetes, and Related Research (U24 Clinical Trial Optional)"
  (NOT-DK-21-017)
  National Institute of Diabetes and Digestive and Kidney Diseases

• **Notice of Change to the Application Due Date(s) for PAR-20-083 titled "Enhancing Regulatory Science for Advancing Pharmaceutical Quality and Manufacturing (U01 Clinical Trials Optional)."
  (NOT-FD-21-013)
  Food and Drug Administration

• **Notice of NICHD Participation in PAR-20-266, "Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional)"
  (NOT-HD-21-021)
  [Eunice Kennedy Shriver National Institute of Child Health and Human Development](https://www.nichd.nih.gov)

• **Notice of NICHD Participation in PAR-21-099, "Music and Health: Understanding And Developing Music Medicine (R21 Clinical Trial Optional)"
• Notice of NICHD Participation in PAR-21-100, "Music and Health: Understanding And Developing Music Medicine (R01 Clinical Trial Optional)"
  (NOT-HD-21-023)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development

• Notice of Change to AIDS Date of RFA-MH-21-120, "Mental Health Research Awards for Investigators Early in their Career in Low and Middle-Income Countries (R01 Clinical Trial Optional)"
  (NOT-MH-21-240)
  National Institute of Mental Health

• Notice of Change to Key Dates for RFA-NS-20-006 "BRAIN Initiative: Biology and Biophysics of Neural Stimulation and Recording Technologies (R01 Clinical Trials Optional)"
  (NOT-NS-21-046)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health

• Notice of Corrections to PAR-20-181, Limited Competition: National Primate Research Centers (P51) (Clinical Trials Not Allowed)
  (NOT-OD-21-081)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

• Notice of Change: Change in Data Table Submission Requirements for PAR-21-120, Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)
  (NOT-TW-21-005)
  John E. Fogarty International Center

Notices of Intent to Publish

• Notice of Intent to Publish Funding Opportunity Announcements for the RADx-UP Initiative (Phase II)
  (NOT-OD-21-064)
  National Institutes of Health
  Office of Research on Women's Health

• Notice of Intent to Publish a Funding Opportunity Announcement for PHS 2021 Omnibus Solicitations of the NIH, CDC, and FDA for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Grant Applications
  (NOT-OD-21-083)
  National Institutes of Health

Notices of Special Interest

• Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies
  (NOT-AI-21-032)
  National Institute of Allergy and Infectious Diseases

• Notice of Special Interest (NOSI): Administrative Supplement for Genome-wide Genotyping of Existing Samples from Minority Racial/Ethnic Populations and Sharing of Associated
Epidemiologic Data
(NOT-CA-21-049)
National Cancer Institute

- **Notice of Special Interest (NOSI): Synthetic Psychoactive Drugs and Strategic Approaches to Counteract Their Deleterious Effects**
  (NOT-DA-21-028)
  National Institute on Drug Abuse

- **Notice of Special Interest (NOSI): Administrative Supplements for research on fentanyl and derivatives**
  (NOT-DA-21-032)
  National Institute on Drug Abuse

- **Notice of Special Interest (NOSI): Basic Research on Fentanyl and Synthetic Fentanyl Analogs: Signaling, Neurobiology, and Pharmacology**
  (NOT-DA-21-033)
  National Institute on Drug Abuse

- **Notice of Special Interest (NOSI): Stimulate Research on the Diagnosis, Treatment, and Mechanistic Understanding of Postural Orthostatic Tachycardia Syndrome (POTS)**
  (NOT-HL-21-008)
  National Heart, Lung, and Blood Institute
  National Institute of Neurological Disorders and Stroke

- **Notice of Special Interest (NOSI): Characterization of Genomics of Induced Pluripotent Stem Cell Lines for AD/ADRD Research**
  (NOT-NS-21-041)
  National Institute of Neurological Disorders and Stroke

- **Notice of Special Interest (NOSI): Administrative Supplement for Providing Technical and Business Assistance (TABA) Funding to SBIR/STTR Awardees (Admin Supp)**
  (NOT-OD-21-062)
  National Institutes of Health
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Biomedical Imaging and Bioengineering
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute of Nursing Research
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

- **Notice of Special Interest (NOSI): Administrative Supplements for COVID-19-Impacted FIC Research Training and Education Awards**
  (NOT-TW-21-003)
  John E. Fogarty International Center

- **Notice of Special Interest (NOSI): Administrative Supplements to FIC Awards for COVID-19-related Research in Low- or Middle-Income Countries**
Funding Opportunities

- **NHGRI Predoctoral to Postdoctoral Transition Award for a Diverse Genomics Workforce (F99/K00)** (PAR-21-143)
  National Human Genome Research Institute
  Application Receipt Date(s): August 8, 2021; December 8, 2021; April 8, 2022; August 8, 2022; December 8, 2022; April 8, 2023; August 8, 2023; December 8, 2023; April 8, 2024 All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

- **Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)** (PAR-21-166)
  National Cancer Institute
  National Institute of Dental and Craniofacial Research
  Application Receipt Date(s): Multiple dates, see announcement.

- **Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)** (PAR-21-183)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.

- **Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)** (PAR-21-206)
  National Cancer Institute
  Application Receipt Date(s): Multiple dates, see announcement.

- **Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)** (PAR-21-208)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.

- **Limited Competition: Alzheimers Disease Sequencing Project Follow-Up Study 2.0 (ADSP FUS 2.0): The Diverse Population Initiative (U01 Clinical Trial Not Allowed)** (PAR-21-212)
  National Institute on Aging
  Application Receipt Date(s): Multiple dates, see announcement.

- **Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Aging (R25 - Clinical Trial Not Allowed)** (RFA-AG-22-009)
  National Institute on Aging
  Application Receipt Date(s): October 4, 2021 - . No late applications will be accepted for this Funding Opportunity Announcement.

- **Short Courses on Interdisciplinary Behavioral and Social Sciences Research on Alzheimer's Disease and Related Dementias (R25 - Clinical Trial Not Allowed)** (RFA-AG-22-010)
Neural Mechanisms of Force-Based Manipulations: High Priority Research Networks (U24 Clinical Trial Optional)
(RFA-AT-21-006)
National Center for Complementary and Integrative Health
National Institute of Neurological Disorders and Stroke
Application Receipt Date(s): Multiple dates, see announcement.

SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies Toward Commercialization (R44 Clinical Trial Optional)
(RFA-CA-21-036)
National Cancer Institute
Application Receipt Date(s): August 6, 2021

Strategies that Support Global Food Safety (U01) Clinical Trial Not Allowed
(RFA-FD-21-030)
Food and Drug Administration
Application Receipt Date(s): May 24, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

AAV Vector manufacturing for diseases affecting very small populations (R01) Clinical Trials Not Allowed
(RFA-FD-21-034)
Food and Drug Administration
Application Receipt Date(s): May 28, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.

Recompetition of the Pediatric Scientist Development Program (PSDP) (K12 Clinical Trial Not Allowed)
(RFA-HD-22-006)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): July 29, 2021

NLM Institutional Grants for Research Training in Biomedical Informatics and Data Science (T15 Clinical Trial Not Allowed)
(RFA-LM-21-001)
National Library of Medicine
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): Multiple dates, see announcement.

Understanding and Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities (R01 Clinical Trial Optional)
(RFA-MD-21-004)
National Institute on Minority Health and Health Disparities
National Center for Complementary and Integrative Health
National Cancer Institute
Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Allowed) (RFA-RM-21-021)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): May 28, 2021

Transformative Research to Address Health Disparities and Advance Health Equity at Minority Serving Institutions (U01 Clinical Trial Allowed) (RFA-RM-21-022)
Office of Strategic Coordination (Common Fund)
Application Receipt Date(s): May 28, 2021

Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research (Collaborative U01 Clinical Trial Optional) (RFA-TW-21-001)
John E. Fogarty International Center
National Cancer Institute
National Institute on Aging
National Institute of Environmental Health Sciences
Office of Research on Women's Health
Application Receipt Date(s): Multiple dates, see announcement.

Hubs of Interdisciplinary Research and Training in Global Environmental and Occupational Health (GEOHealth) Research Training (Collaborative U2R Clinical Trial Optional) (RFA-TW-21-002)
John E. Fogarty International Center
National Cancer Institute
National Institute on Aging
National Institute of Environmental Health Sciences
Office of Research on Women's Health
Application Receipt Date(s): July 8, 2021 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to
allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

NIH Funding Opportunities now available in RSS (Really Simple News Syndication) format - see https://grants.nih.gov/grants/guide/rss_info.htm for details.

To UnSubscribe from the NIH Guide Weekly TOC LISTSERV, follow the instructions at https://grants.nih.gov/grants/guide/listserv.htm